Public Statement:

Macular (or foveal) translocation for macular degeneration is not covered.

Medical Policy Statement:

Macular translocation is considered experimental or investigational and is not covered.

Background:

Translocation of the fovea is performed for macular degeneration. The movement of the fovea is to an area with healthier pigment epithelium. The procedure was first reported in 1983 in animals, and reported in humans in 1993. Early success was followed by complications. No randomized, controlled trials have compared submacular surgery with placebo.

References:


Application to Products

This policy applies to ARBenefits. Consult ARBenefits Summary Plan Description (SPD) for additional information.

Last modified by: Date: